KRAS mutant lung adenocarcinomas are often diagnosed with co-occurring TP53 alterations, including loss or gain of function, that are usually associated with shorter PFS and increased metastasis probability [34,35]. The gene discussed is KRAS; the disease is lung adenocarcinoma.